Emerald Advisers, LLC Applied Therapeutics Inc. Transaction History

Emerald Advisers, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$1.48 - $6.22 $905,057 - $3.8 Million	-611,525 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$8.77 - $18.29 $401,639 - $837,627	45,797 Added 8.1%	611,525 $5.47 Million
Q3 2021 Oct 28, 2021	SELL	$13.54 - $22.06 $45,155 - $73,570	-3,335 Reduced 0.59%	565,728 $9.39 Million
Q2 2021 Jul 29, 2021	BUY	$14.05 - $25.04 $207,715 - $370,191	14,784 Added 2.67%	569,063 $11.8 Million
Q1 2021 Apr 29, 2021	BUY	$16.57 - $28.65 $638,856 - $1.1 Million	38,555 Added 7.48%	554,279 $10.4 Million
Q4 2020 Jan 29, 2021	BUY	$15.44 - $24.23 $164,420 - $258,025	10,649 Added 2.11%	515,724 $11.4 Million
Q3 2020 Oct 28, 2020	BUY	$19.43 - $35.36 $2.02 Million - $3.67 Million	103,744 Added 25.85%	505,075 $10.5 Million
Q2 2020 Jul 28, 2020	BUY	$29.41 - $51.23 $2.72 Million - $4.73 Million	92,378 Added 29.9%	401,331 $14.5 Million
Q1 2020 Apr 30, 2020	BUY	$19.54 - $55.47 $5.5 Million - $15.6 Million	281,688 Added 1033.15%	308,953 $10.1 Million
Q4 2019 Jan 29, 2020	BUY	$10.16 - $28.14 $173,949 - $481,784	17,121 Added 168.78%	27,265 $744,000
Q3 2019 Oct 31, 2019	BUY	$8.08 - $10.99 $81,963 - $111,482	10,144 New	10,144 $111,000

139

111M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $28.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.